Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii + Dicetel for IBS-D (Phase 4, China)
ChiCTR2500105272Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Dicetel monotherapy with Dicetel + Saccharomyces boulardii (2 arms). Primary endpoint: IBS-SSS at 4 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
pinaveriumsaccharomyces boulardii
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2500105272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105272.